Andre F E
Postgrad Med J. 1985;61 Suppl 4:113-20.
Sufficient safety and efficacy data have been obtained on a live varicella vaccine (Varilrix, Smith Kline-RIT) derived from the Oka-strain attenuated varicella-zoster virus to justify its recent licensure in several European countries for use in special indication groups. This review article summarizes the data obtained in Japan, Europe, and the United States. In addition, a survey of the published literature on clinical studies performed on as yet unlicensed Oka-strain varicella vaccines produced by the Biken Institute and Merck Sharp & Dohme is presented.
已从源自Oka株减毒水痘-带状疱疹病毒的活水痘疫苗（Varilrix，史克-里特）获得了足够的安全性和有效性数据，证明其近期在几个欧洲国家获批用于特定适应症群体是合理的。这篇综述文章总结了在日本、欧洲和美国获得的数据。此外，还介绍了对日本国立预防卫生研究所和默克公司生产的尚未获批的Oka株水痘疫苗进行的临床研究的已发表文献调查。
